AtriCure (NASDAQ:ATRC) Director Sells $138,283.20 in Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Karen Prange also recently made the following trade(s):

• On Wednesday, May 20th, Karen Prange sold 3,000 shares of AtriCure stock. The stock was sold at an average price of $28.65, for a total transaction of $85,950.00.

AtriCure Price Performance

NASDAQ ATRC opened at $41.39 on Monday. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18. The company has a market capitalization of $2.11 billion, a P/E ratio of 197.10 and a beta of 1.20. The company’s 50 day simple moving average is $32.25 and its 200 day simple moving average is $31.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in AtriCure by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after acquiring an additional 62,861 shares in the last quarter. BlackRock Inc. acquired a new position in shares of AtriCure in the 2nd quarter valued at about $125,198,000. Wellington Management Group LLP lifted its position in shares of AtriCure by 8.1% in the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after purchasing an additional 322,818 shares in the last quarter. First Light Asset Management LLC boosted its holdings in shares of AtriCure by 32.0% during the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after purchasing an additional 285,083 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of AtriCure by 8.2% during the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after purchasing an additional 75,862 shares during the period. 99.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ATRC has been the topic of a number of recent research reports. Weiss Ratings upgraded AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Canaccord Genuity Group increased their price target on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. UBS Group cut their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Finally, Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.50.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.